An innovative design to establish proof of concept of the antidepressant effects of the nr2b subunit selective n-methyl-d-aspartate antagonist, cp-101,606, in patients with treatment-refractory major depressive disorder / Sheldon H. Preskorn en Journal of Clinical Psychopharmacology, Año 2008 - Vol. 28 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 6 (Diciembre) . - pp. 631-637 Título : An innovative design to establish proof of concept of the antidepressant effects of the nr2b subunit selective n-methyl-d-aspartate antagonist, cp-101,606, in patients with treatment-refractory major depressive disorder Tipo de documento: texto impreso Autores: Sheldon H. Preskorn, Autor ; Bryan Baker, Autor ; Sheela Kolluri, Autor Fecha de publicación: 2023 Artículo en la página: pp. 631-637 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agentes antidepresivos, Trastorno depresivo mayor, Resistencia a las drogas, Antagonistas de aminoácidos excitadores, Paroxetina, Piperidinas, Inhibidores selectivos de la recaptación de serotonina, Índice de gravedad de la enfermedad. Resumen: This randomized, placebo-controlled, double-blind study was the first to evaluate the antidepressant efficacy, safety, and tolerability of an NR2B subunit-selective N-methyl-D-aspartate receptor antagonist, CP-101,606. Subjects had major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and a history of treatment refractoriness to least 1 adequate trial of a selective serotonin reuptake inhibitor. Link: ./index.php?lvl=notice_display&id=30821 [artículo] An innovative design to establish proof of concept of the antidepressant effects of the nr2b subunit selective n-methyl-d-aspartate antagonist, cp-101,606, in patients with treatment-refractory major depressive disorder [texto impreso] / Sheldon H. Preskorn, Autor ; Bryan Baker, Autor ; Sheela Kolluri, Autor . - 2023 . - pp. 631-637. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 6 (Diciembre) . - pp. 631-637 Palabras clave: Agentes antidepresivos, Trastorno depresivo mayor, Resistencia a las drogas, Antagonistas de aminoácidos excitadores, Paroxetina, Piperidinas, Inhibidores selectivos de la recaptación de serotonina, Índice de gravedad de la enfermedad. Resumen: This randomized, placebo-controlled, double-blind study was the first to evaluate the antidepressant efficacy, safety, and tolerability of an NR2B subunit-selective N-methyl-D-aspartate receptor antagonist, CP-101,606. Subjects had major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and a history of treatment refractoriness to least 1 adequate trial of a selective serotonin reuptake inhibitor. Link: ./index.php?lvl=notice_display&id=30821

---

1 (1 - 1 / 1)